ANN ARBOR, Mich.--(BUSINESS WIRE)--Aug. 1, 2019--
Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that management will present company overviews and conduct one-on-one investor meetings at the following healthcare investor conferences:
- SVB Leerink Spotlight Series: Rare & Genetic Diseases on Wednesday, August 7, 2019 in Boston. Management will present a company overview in a fireside chat format at 2:00 p.m. EDT.
- 2019 Wedbush PacGrow Healthcare Conferenceon Wednesday, August 14, 2019 at 9:10 a.m. EDT in New York. A live webcast of the presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. For more information, please visit www.millendo.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190801005100/en/
Source: Millendo Therapeutics, Inc.
Millendo Investor Contact:
Stern Investor Relations
Millendo Media Contact: